Drug associations as alternative and complementary therapy for neglected tropical diseases
| Autor: | Myla Lôbo de Souza, Victor de Albuquerque Wanderley Sales, Widson Michael Dos Santos, Mateus Chaves de Andrade, Pedro José Rolim-Neto, Larissa Pereira Alves, Laysa Creusa Paes Barreto Barros Silva, Leslie Raphael de Moura Ferraz, Larissa Araújo Rolim, Ilka do Nascimento Gomes Barbosa |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Complementary Therapies
medicine.medical_specialty business.industry Veterinary (miscellaneous) Public health Psychological intervention MEDLINE Neglected Diseases Tropical disease Disease medicine.disease Praziquantel Drug repositioning Infectious Diseases Pharmaceutical Preparations Insect Science SAFER medicine Neglected tropical diseases Humans Schistosomiasis Parasitology business Intensive care medicine |
| Zdroj: | Acta Tropica. 225:106210 |
| ISSN: | 0001-706X |
| DOI: | 10.1016/j.actatropica.2021.106210 |
| Popis: | The present paper aims to establish different treatments for neglected tropical disease by a survey on drug conjugations and possible fixed-dose combinations (FDC) used to obtain alternative, safer and more effective treatments. The source databases used were Science Direct and PubMed/Medline, in the intervals between 2015 and 2021 with the drugs key-words or diseases, like "schistosomiasis", "praziquantel", "malaria", "artesunate", "Chagas' disease", "benznidazole", "filariasis", diethylcarbamazine", "ivermectin", " albendazole”. 118 works were the object of intense analysis, other articles and documents were used to increase the quality of the studies, such as consensuses for harmonizing therapeutics and historical articles. As a result, an effective NTD control can be achieved when different public health approaches are combined with interventions guided by the epidemiology of each location and the availability of appropriate measures to detect, prevent and control disease. It was also possible to verify that the FDCs promote a simplification of the therapeutic regimen, which promotes better patient compliance and enables a reduction in the development of parasitic resistance, requiring further studies aimed at resistant strains, since the combined APIs usually act by different mechanisms or at different target sites. In addition to eliminating the process of developing a new drug based on the identification and validation of active compounds, which is a complex, long process and requires a strong long-term investment, other advantages that FDCs have are related to productive gain and gain from the industrial plant, which can favor and encourage the R&D of new FDCs not only for NTDs but also for other diseases that require the use of more than one drug. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect